Beyond lipid lowering: The role of statins in vascular protection

International Journal of Cardiology

Volumn 86, Issue 1, 2002, Pages 5-18

  Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C Reactive protein; Coronary heart disease; Endothelial dysfunction; HMG CoA reductase inhibitor; Low density lipoprotein cholesterol; Pleiotropic

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LFA 703; LIPID; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); PLEIOTROPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOVASCULARIZATION, PHYSIOLOGIC; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN;

EID: 0036829777     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00195-X     Document Type: Review

References (156)

1. World Health Organization . World Health Report. Report of the Director-General. 1998;WHO, Geneva.
2. Kastelein J.J.P. The future of best practice. Atherosclerosis. 143:(Suppl 1):1999;S17-S21.
3. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol lipoproteins and risk of coronary heart disease: the Framingham study. Ann Intern Med. 74:1971;1-12.
4. Abbott R.D., Wilson P.W.F., Kannel W.B., Castelli W.P. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham study. Arteriosclerosis. 8:1988;207-211.
5. Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc. 256:1986;2823-2828.
6. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
7. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
8. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
9. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc. 279:1998;1615-1622.
10. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
11. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J Am Med Assoc. 279:1998;1643-1650.
12. Davignon J., Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 10:1999;543-559.
13. Bellosta S., Ferri N., Arnaboldi L., Bernini F., Paoletti R., Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 23:(Suppl 2):2000;B72-B78.
14. Faggiotto A., Paoletti R. Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins? Curr Atheroscler Rep. 2:2000;20-25.
15. Laufs U., Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 10:2000;143-148.
16. Vaughan C.J., Gotto A.M. Jr, Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 35:2000;1-10.
17. LaRosa J.C. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. 88:2001;291-293.
18. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 49:2001;281-287.
19. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
20. Ohnaka K., Shimoda S., Nawata H., et al. Pitavastatin enhances BMP-2 and osteocalcin expression by inhibition of rho-associated kinase in human osteblasts. Biochem Biophys Res Commun. 287:2001;337-342.
21. Ho-Ming Chan M., Wing-Lai Mak T., Wai-Kwun Chiu R., Chow C.C., Hiu-Shuen Chan I., Wai-Kei Lam C. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 86:2001;4556-4559.
22. Chan K.A., Andrade S.E., Boles M., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188.
23. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc. 283:2000;3205-3210.
24. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. J Am Med Assoc. 283:2000;3211-3216.
25. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 86:2001;4556-4559.
26. Vogel R.A. Cholesterol lowering and endothelial function. Am J Med. 107:1999;479-487.
27. Berliner J.A., Schwartz D.S., Territo M.C., et al. Induction of chemotactic cytokines by minimally oxidized LDL. Adv Exp Med Biol. 351:1993;13-18.
28. O'Brien K.D., Allen M.D., McDonald T.O., et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest. 92:1993;945-951.
29. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis. 147:1999;213-225.
30. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
31. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 141:2001;211-217.
32. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation. 97:1998;946-952.
33. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomised controlled trial. J Am Med Assoc. 285:2001;1711-1718.
34. Sacks F.M. Lipid-lowering therapy in acute coronary syndromes. J Am Med Assoc. 285:2001;1758-1760.
35. West of Scotland Coronary Prevention Study Group . Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
36. Scandinavian Simvastatin Survival Study Group . Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 345:1995;1274-1275.
37. Collins R., Peto R., Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract. 56:2002;53-56.
38. Prospective Studies Collaboration . Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 346:1995;1647-1653.
39. Blauw G.J., Lagaay A.M., Smelt A.H.M., Westendorp R.G.J. Stroke, statins and cholesterol. Stroke. 28:1997;946-950.
40. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc. 278:1997;313-321.
41. Pedersen T.R., Kjekshus J., Pyörälä K., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 81:1998;333-335.
42. Dechend R., Fieber A., Park J.-K., et al. Amelioration of angiotension II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation. 104:2001;576-581.
43. Glorioso N., Troffa C., Filigheddu F., et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 34:1999;1281-1286.
44. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent vasomotion. N Engl J Med. 332:1995;488-493.
45. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
46. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
47. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 39:1997;287-324.
48. Anderson T.J. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 34:1999;631-638.
49. Stehouwer C.D.A. Is measurement of endothelial dysfunction clinically useful? Eur J Clin Invest. 29:1999;459-461.
50. Sica D.A. Endothelial cell function: new considerations. Eur Heart J. 2:(Suppl B):2000;B13-B21.
51. Shimokawa H., Vanhoutte P.M. Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. J Am Coll Cardiol. 13:1989;1402-1408.
52. Simon B.C., Cunningham L.D., Cohen R.A. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 86:1990;75-79.
53. Galle J., Bengen J., Schollmeyer P., Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation. 92:1995;1582-1589.
54. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
55. John S., Schlaich M., Langenfeld M., et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 98:1998;211-216.
56. Cayette A.J., Palacino J.J., Horten K., Cohen R.A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 14:1994;753-759.
57. Koh K.K. Effects of statin on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 47:2000;648-657.
58. Laufs U., La Fata V., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 272:1997;31725-31729.
59. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 273:1998;24266-24271.
60. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
61. Laufs U., Endres M., Stagliano N., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 106:2000;15-24.
62. Laufs U., Endres M., Custodis F., et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 102:2000;3104-3110.
63. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 33:1999;234-241.
64. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
65. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signalling networks. Genes Dev. 11:1997;2295-2322.
66. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
67. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidised low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 270:1995;317-324.
68. Scalia R., Gooszen M.E., Jones S.P., et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apoliopoprotein E-deficient mice. Circulation. 103:2001;2598-2603.
69. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 100:1997;3131-3139.
70. Endres M., Laufs U., Huang Z., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 95:1998;8880-8885.
71. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184.
72. Libby P. Changing concepts of atherogenesis. J Intern Med. 246:2000;349-358.
73. Hussein O., Schlezinger S., Rosenblat M., Keider M., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
74. Suzumura K., Yasuhara M., Tanaka K., Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol. 57:1999;697-703.
75. Yasuhara M., Suzumura K., Tanaka K., et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull. 23:2000;570-574.
76. Rikitake Y., Kawashima S., Takeshita S., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atheroscelrosis. 154:2001;87-96.
77. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 138:1998;271-280.
78. Pietsch A., Erl W., Lorenz R.L. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol. 52:1996;433-439.
79. Umetani N., Kanayama Y., Okamura M., Negoro N., Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor on THP-I human macrophages. Biochim Biophys Acta. 1303:1996;199-206.
80. Draude G., Hrboticky N., Lorenz R.L. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol. 57:1999;383-386.
81. Takemoto M., Node K., Nakagami H., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 108:2001;1429-1437.
82. Wassmann S., Laufs U., Baumer A.T., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 59:2001;646-654.
83. Dusi S., Donini M., Rossi F. Mechanisms of NADPH oxidase activation in human neutrophils: p67phox is required for the translocation of rac 1 but not of rac 2 from cytosol to the membranes. Biochem J. 308:1995;991-994.
84. Rinckel L.A., Faris S.L., Hitt N.D., Kleinberg M.E. Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation. Biochem Biophys Res Commun. 263:1999;118-122.
85. Isner J.M., Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 103:1999;1231-1236.
86. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
87. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967.
88. Shi Q., Rafii S., Wu M.H., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 92:1998;632-637.
89. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:1999;221-228.
90. Risau W., Sariola H., Zerwes H.G., et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development. 102:1988;471-478.
91. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 108:2001;391-397.
92. Llevadot J., Murasawa S., Kurerishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 108:2001;399-405.
93. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 103:2001;2885-2890.
94. Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation. 99:1999;2871-2875.
95. Jones S.P., Trocha S.D., Lefer D.J. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol. 21:2001;2059-2064.
96. Vaughan C.J., Murphy M.B., Buckely B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
97. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
98. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total an HDL cholesterol in determining risk of first myocardial infarction. Circulation. 97:1998;2007-2011.
99. Koenig W., Sund M., Frohlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
100. Rohde L.E., Hennekens C.H., Ridker P.M. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 84:1999;1018-1022.
101. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
102. Mendall M.A., Patel P., Ballam L., Strachan D., Northfield T.C. C-reactive protein and its relation to cardiovascular risk factors: a population-based cross-sectional study. Br Med J. 312:1996;1061-1065.
103. Maseri A. Inflammation, atherosclerosis and ischemic events - exploring the hidden side of the moon. N Engl J Med. 336:1997;1014-1016.
104. Anderson J.L., Carlquist J.F., Muhlestein J.B., Horne B.D., Elmer S.P. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 32:1998;35-41.
105. Baumann H., Gauldie J. The acute phase response. Immunol Today. 15:1994;74-80.
106. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 19:1999;2348-2354.
107. Zhang Y.X., Cliff W.J., Schoefl G.I., Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 145:1999;375-379.
108. Torzewski J., Bowyer D.E., Waltenberger J., Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis. 132:1997;131-138.
109. Rossen R.D. HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs? J Am Coll Cardiol. 30:1997;1218-1219.
110. Diomede L., Albani D., Sottocorno M., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 21:2001;1327-1332.
111. Niwa S., Totsuka T., Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol. 18:1996;669-675.
112. Weitz-Schmidt G., Welzenbach K., Brinkman V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 7:2001;687-692.
113. Kimura M., Kurose I., Russell J., Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 17:1997;1521-1526.
114. Pruefer D., Scalia R., Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 19:1999;2894-2900.
115. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E., for the Cholesterol and Recurrent Events (CARE) Investigators . Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
116. Ridker P.M., Miles J.S., Downs J.R., et al. Lovastatin 20-40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS. Circulation. 102:(Suppl):2000;II833.
117. Ridker P.M., Rifai N., Pitman Lowenthal S. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
118. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 353:1999;983-984.
119. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 77:2001;247-253.
120. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomised trial and cohort study. J Am Med Assoc. 286:2001;64-70.
121. Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:1998;82-89.
122. Kip1. J Biol Chem. 274:1999;21926-21931.
123. Baetta R., Donetti E., Comparato C., et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res. 36:1997;115-121.
124. Buemi M., Allegra A., Senatore M., et al. Pro-atoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol. 370:1999;201-203.
125. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Meierhofer C., Djanani A., Wiedermann C.J. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis. 158:2001;23-33.
126. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., Fallon J.T. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 90:1994;775-778.
127. Fuster V., Stein B., Ambrose J.A., Badimon L., Badimon J.J., Chesebro J.H. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 82:(Suppl II):1990;47-59.
128. Henney A.M., Wakeley P.R., Davies M.J., et al. Location of stromelysin gene expression in atherosclerotic plaques by in situ hybridisation. Proc Natl Acad Sci USA. 88:1991;8154-8158.
129. Richardson P.D., Davies M.J., Born G.V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaque. Lancet. 2:1989;941-944.
130. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 92:1995;1565-1569.
131. Davies M.J. Acute coronary thrombosis - the role of plaque disruption and its initiation and prevention. Eur Heart J. 16:(Suppl L):1995;3-7.
132. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933.
133. Fitzgerald D.J., Roy L., Catella F., Fitzgerald G.A. Platelet activation in unstable coronary disease. N Engl J Med. 315:1986;983-989.
134. Willerson J.T., Golino P., Eidt J., Campbell W.B., Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 80:1989;198-205.
135. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
136. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
137. Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;247-251.
138. 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. Clin Pharmacol Ther. 61:1997;684-691.
139. 2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol. 15:1995;759-764.
140. Mazeaud M.M., Driss F., Le Quan Sang K.H., et al. Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients. Atherosclerosis. 94:1992;201-211.
141. Mayer J., Eller T., Brauer P., et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 64:1992;196-201.
142. Degraeve F., Bolla M., Blaie S., et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells: Involvement of geranylgeranylated proteins. J Biol Chem. 276:2001;46849-46855.
143. Lijnen P., Celis H., Fagard R., et al. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens. 12:1994;59-64.
144. Alfon J., Pueyo Palazon C., Royo T., Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipidemic rabbit model. Thromb Haemost. 81:1999;822-827.
145. Alfon J., Royo T., Garcia-Moll X., Badimon L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol. 19:1999;1812-1817.
146. Bourcier T., Libby P. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 20:2000;556-562.
147. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
148. Saito Y., Goto Y., Japan Itavastatin Clinical Study Group . Efficacy and safety of NK-104 (itavastatin) in hyperlipidemic subjects: a double-blind comparative study. Atherosclerosis. 151:2000;154.
149. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk. 8:2001;383-390.
150. Davidson M., Ma P., Stein E.A., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or llb hypercholesterolemia. Am J Cardiol. 89:2002;268-275.
151. Shepherd J., Hunninghake D., Harris S., Hutchinson H., Pears J. A review of the safety profile of rosuvastatin in an internal phase II/III clinical trial programme. Int J Clin Pract. Suppl 124:2002;15.
152. Li W., Asagami T., McTaggart F., Tsao P.S. Rosuvastatin inhibits monocyte/endothelial interactions in ApoE (-/-) mice. Int J Clin Pract. Suppl 124:2002;5.
153. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292:2001;1160-1164.
154. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 84:1999;413-423.
155. Rauchhaus M., Koloczek V., Volk H.-D., et al. Inflammatory cytokines and the possible immunological role for the lipoproteins in chronic heart failure. Int J Cardiol. 76:2000;125-133.
156. Rauchhaus M., Coats A.J.S., Anker A.D. The endotoxin-lipoprotein hypothesis. Lancet. 356:2000;930-933.